- Home
- INDP vs TLPH Comparison
INDP vs TLPH Comparison
Compare INDP & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INDP
- TLPH
- Stock Information
- Founded
- INDP 2000
- TLPH 2005
- Country
- INDP United States
- TLPH United States
- Employees
- INDP N/A
- TLPH N/A
- Industry
- INDP Biotechnology: Pharmaceutical Preparations
- TLPH Biotechnology: Pharmaceutical Preparations
- Sector
- INDP Health Care
- TLPH Health Care
- Exchange
- INDP Nasdaq
- TLPH Nasdaq
- Market Cap
- INDP 5.0M
- TLPH 10.6M
- IPO Year
- INDP N/A
- TLPH 2011
- Fundamental
- Price
- INDP $11.00
- TLPH $0.45
- Analyst Decision
- INDP Strong Buy
- TLPH Strong Buy
- Analyst Count
- INDP 2
- TLPH 1
- Target Price
- INDP $8.50
- TLPH $6.00
- AVG Volume (30 Days)
- INDP 689.8K
- TLPH 42.9K
- Earning Date
- INDP 08-11-2025
- TLPH 08-13-2025
- Dividend Yield
- INDP N/A
- TLPH N/A
- EPS Growth
- INDP N/A
- TLPH N/A
- EPS
- INDP N/A
- TLPH N/A
- Revenue
- INDP N/A
- TLPH $27,000.00
- Revenue This Year
- INDP N/A
- TLPH N/A
- Revenue Next Year
- INDP N/A
- TLPH $14,533.26
- P/E Ratio
- INDP N/A
- TLPH N/A
- Revenue Growth
- INDP N/A
- TLPH N/A
- 52 Week Low
- INDP $7.56
- TLPH $0.43
- 52 Week High
- INDP $66.64
- TLPH $1.19
- Technical
- Relative Strength Index (RSI)
- INDP 51.26
- TLPH 45.62
- Support Level
- INDP $9.45
- TLPH $0.45
- Resistance Level
- INDP $13.44
- TLPH $0.52
- Average True Range (ATR)
- INDP 2.06
- TLPH 0.03
- MACD
- INDP 0.19
- TLPH -0.00
- Stochastic Oscillator
- INDP 28.75
- TLPH 35.33
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.